Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Dissecting the role of redox signaling in neuronal development.

Bórquez DA, Urrutia PJ, Wilson C, van Zundert B, Núñez MT, González-Billault C.

J Neurochem. 2016 May;137(4):506-17. doi: 10.1111/jnc.13581. Epub 2016 Apr 8. Review.

2.

Searching for novel Cdk5 substrates in brain by comparative phosphoproteomics of wild type and Cdk5-/- mice.

Contreras-Vallejos E, Utreras E, Bórquez DA, Prochazkova M, Terse A, Jaffe H, Toledo A, Arruti C, Pant HC, Kulkarni AB, González-Billault C.

PLoS One. 2014 Mar 21;9(3):e90363. doi: 10.1371/journal.pone.0090363. eCollection 2014.

3.

Bioinformatic survey for new physiological substrates of Cyclin-dependent kinase 5.

Bórquez DA, Olmos C, Álvarez S, Di Genova A, Maass A, González-Billault C.

Genomics. 2013 Apr;101(4):221-8. doi: 10.1016/j.ygeno.2013.01.003. Epub 2013 Feb 4.

4.

The amyloid precursor protein intracellular domain-fe65 multiprotein complexes: a challenge to the amyloid hypothesis for Alzheimer's disease?

Bórquez DA, González-Billault C.

Int J Alzheimers Dis. 2012;2012:353145. doi: 10.1155/2012/353145. Epub 2012 Feb 9.

5.

Regulation of cell polarity by controlled proteolytic systems.

Bórquez DA, González-Billault C.

Biol Res. 2011;44(1):35-41. doi: 10.4067/S0716-97602011000100005. Epub 2011 May 11. Review.

6.

Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer.

Welt A, von Minckwitz G, Oberhoff C, Borquez D, Schleucher R, Loibl S, Harstrick A, Kaufmann M, Seeber S, Vanhoefer U.

Ann Oncol. 2005 Jan;16(1):64-9.

PMID:
15598940
7.

High-dose chemotherapy with autologous stem cell transplantation in patients with oligometastatic breast cancer.

Bojko P, Welt A, Schleucher R, Borquez D, Scheulen ME, Vanhoefer U, Poettgen C, Stuschke M, Broelsch CE, Stamatis G, Wilke H, Seeber S, Harstrick A.

Bone Marrow Transplant. 2004 Oct;34(7):637-43.

PMID:
15300229
8.

Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer.

Bianchi G, Albanell J, Eiermann W, Vitali G, Borquez D, Viganò L, Molina R, Raab G, Locatelli A, Vanhauwere B, Gianni L, Baselga J.

Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5944-51.

9.
10.

Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Essen Breast Cancer Study Group.

Kloke O, Klaassen U, Oberhoff C, Hartwich G, Szanto J, Wolf E, Heckmann M, Huhn R, Stephan L, Schnepper U, Donsbach GM, Bechtel C, Rudolph R, Berke A, Borquez D, Hawig I, Hirche H, Schindler AE, Seeber S, Becher R.

Breast Cancer Res Treat. 1999 May;55(1):51-9.

PMID:
10472779
11.

Paclitaxel and UFT plus oral calcium folinate in pretreated metastatic breast cancer.

Klaassen U, Borquez D, Lang S, Oberhoff C, Harstrick A, Seeber S, Benner S.

Oncology (Williston Park). 1999 Jul;13(7 Suppl 3):71-3.

12.

Infusional 5-fluorouracil/leucovorin plus paclitaxel and cisplatin in the first-line treatment of metastatic breast cancer: results of a phase II study.

Klaassen U, Wilke H, Müller C, Borquez D, Harstrick A, Seeber S.

Semin Oncol. 1997 Oct;24(5 Suppl 17):S17-58-S17-60.

PMID:
9374095
13.

Infusional 5-FU, folinic acid, paclitaxel, and cisplatin for metastatic breast cancer.

Klaassen U, Wilke H, Müller C, Borquez D, Korn M, Achterrath W, Harstrick A, Diergarten K, Seeber S.

Oncology (Williston Park). 1997 Apr;11(4 Suppl 3):38-40.

14.

Muscarinic cholinoceptors in the human heart: demonstration, subclassification, and distribution.

Deighton NM, Motomura S, Borquez D, Zerkowski HR, Doetsch N, Brodde OE.

Naunyn Schmiedebergs Arch Pharmacol. 1990 Jan-Feb;341(1-2):14-21.

PMID:
2314479

Supplemental Content

Loading ...
Support Center